Dec 21, 2023 8:00am EST Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
Dec 14, 2023 4:15pm EST Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
Oct 25, 2023 7:30am EDT Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
Oct 17, 2023 8:00am EDT Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Sep 20, 2023 7:30am EDT Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
Aug 16, 2023 7:30am EDT Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US
Aug 14, 2023 8:00am EDT Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update
